Nightingale EOS - About Us

About Us
Nightingale-EOS Limited’s business model is to take advanced process-control technology from the semiconductor industry - perhaps the most intensive high-volume high-precision manufacturing industry that there is - and generate value by making that technology available in other industrial sectors. In this first phase of the company’s development, the emphasis is upon taking a proven coating thickness measurement technology, Beam Profile Reflectometry, and making it available to medical device manufacturers to help them meet the challenges presented by the FDA’s Process Analytical Technology (PAT) initiative. The company’s senior management team brings together a seasoned semiconductor-industry technologist and a well-respected veteran of the medical device manufacturing industry.
	Dr. Stephen Morris (Founder, Managing Director) was previously Director of Marketing at Therma-Wave Inc., a leading manufacturer of ion implant and thin-film metrology equipment for the semiconductor industry. Therma-Wave has since been acquired by KLA-Tencor Inc., one of the largest suppliers of manufacturing and process-control equipment in that industry. Prior to taking the marketing role, he worked on the technology side of the business as a senior process development scientist. Before entering the semiconductor industry, he had also worked in the marine and aerospace industries. He is a graduate of the University of Manchester, and has a PhD in Physics from Cardiff University and an MSc in technology management from the Manchester Business School.

	Alistair Taylor (Chairman) has spent his entire career in the pharmaceutical and medical device industries. After ten years with Beecham Pharmaceuticals Limited from 1963 to 1973, he spent the next nineteen years with Pfizer Hospital Products where he became Vice President of Business Development (based in New York) and CEO of the Schneider Inc. subsidiary which introduced the world’s first cardiac stent and the market-leading ‘Monorail’ angioplasty catheter. He then moved back to the UK as CEO of Biocompatibles PLC, where between 1993 and 1999 he took the company public at a valuation of $135 million and raised over $200 million in funds. Among other projects, the company developed a stent coating technology which was eventually sold to Abbott Laboratories in 2002 for $234 million. From 2000 to 2007 he served as Executive Chairman at Lombard Medical Technologies PLC, where he raised $100m in investment and steered the company from the start-up stage through clinical trials to the commercial launch of numerous FDA-certified and CE-marked products in the US and European markets. He also recruited the firm’s CEO and established the US headquarters in Boston, building the management teams in both the UK and US locations.